Metalloproteinase-Dependent TLR2 Ectodomain Shedding is Involved in Soluble Toll-Like Receptor 2 (sTLR2) Production

Autor: Langjahr, P., Diaz-Jimenez, D., De La Fuente, M., Rubio, E., Golenbock, D., Bronfman, F. C., Quera, R., Lez M.-J.G., Hermoso, M.A., Benjamim C.F.
Jazyk: angličtina
Rok vydání: 2014
Předmět:
ADAM10
Cell Membranes
lcsh:Medicine
Gene Expression
Ligands
Biochemistry
Monocytes
ADAM10 Protein
Animal Cells
Molecular Cell Biology
Medicine and Health Sciences
ADAM17 Protein
Receptor
lcsh:Science
Toll-like receptor
Innate Immune System
Multidisciplinary
Immune System Proteins
Cell biology
Ectodomain
Cellular Structures and Organelles
Cellular Types
Research Article
Immune Cells
Immunology
Molecular Sequence Data
Biology
Lipopeptides
Cell surface receptor
Cell Line
Tumor

Genetics
Humans
Amino Acid Sequence
Innate immune system
lcsh:R
Cell Membrane
Interleukin-8
Immunity
Biology and Life Sciences
Proteins
Membrane Proteins
Cell Biology
Toll-Like Receptor 2
Protein Structure
Tertiary

Enzyme Activation
TLR2
ADAM Proteins
Solubility
Immune System
Metalloproteases
lcsh:Q
Protein Translation
Clinical Immunology
Amyloid Precursor Protein Secretases
Protein Processing
Post-Translational
Zdroj: PLOS ONE
Artículos CONICYT
CONICYT Chile
instacron:CONICYT
PLoS ONE
PLoS ONE, Vol 9, Iss 12, p e104624 (2014)
Popis: Toll-like receptor (TLR) 2, a type I membrane receptor that plays a key role in innate immunity, recognizes conserved molecules in pathogens, and triggering an inflammatory response. It has been associated with inflammatory and autoimmune diseases. Soluble TLR2 (sTLR2) variants have been identified in human body fluids, and the TLR2 ectodomain can negatively regulate TLR2 activation by behaving as a decoy receptor. sTLR2 generation does not involve alternative splicing mechanisms, indicating that this process might involve a post-translational modification of the full-length receptor; however, the specific mechanism has not been studied. Using CD14+ peripheral human monocytes and the THP-1 monocytic leukemia-derived cell line, we confirm that sTLR2 generation increases upon treatment with pro-inflammatory agents and requires a post-translational mechanism. We also find that the constitutive and ligand-induced release of sTLR2 is sensitive to pharmacological metalloproteinase activator and inhibitors leading us to conclude that metalloproteinase TLR2 shedding contributes to soluble receptor production. By expressing human TLR2 in ADAM10- or ADAM17-deficient MEF cells, we find both enzymes to be implicated in TLR2 ectodomain shedding. Moreover, using a deletion mutant of the TLR2 juxtamembrane region, we demonstrate that this domain is required for sTLR2 generation. Functional analysis suggests that sTLR2 generated by metalloproteinase activation inhibitsTLR2-induced cytokine production by this monocytic leukemia-derived cell line. The identification of the mechanisms involved in regulating the availability of soluble TLR2 ectodomain and cell surface receptors may contribute further research on TLR2-mediated processes in innate immunity and inflammatory disorders.
Databáze: OpenAIRE